Friday, July 10, 2026
🇺🇸 FDA

pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A

Chiesi Farmaceutici S.p.A trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT HQ
6,080 Employees
EMA registrant Type
Company details
Status
Public
HQ
Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
Employees
6,080
Programs
20
Drugs
38
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Chiesi Farmaceutici S.p.A clinical trials

Registry index of 20 ClinicalTrials.gov studies linked to Chiesi Farmaceutici S.p.A programs — each row shows trial ID, program name, phase, status, and indication.

Chiesi Farmaceutici S.p.A trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Chiesi Farmaceutici S.p.A.

  1. CLI-06795AA1-09 — Phase 1

    Clinical update

  2. CLI-06001AA1-14 — Phase 1

    Clinical update

  3. CLI-06657AA1-03 — Phase 3

    Clinical update

  4. CLI-06657AA1-01 — Phase 3

    Clinical update

  5. CLI-06467AC1-02 — Phase 1

    Clinical update

  6. CLI-06001AA1-06 — Phase 1

    Clinical update

  7. CLI-06001AA1-05 — Phase 3

    Clinical update

  8. CLI-06001AA1-04 — Phase 3

    Clinical update

Trial registry

20 studies
  2. 2023-507300-30-00

    CLI-06001AA1-14

    Phase 1 active other

    This study is a phase I trial to investigate the effect of inhibition of CYP3A4/5 by Erythromycin on the pharmacokinetics of CHF6001 in healthy volunteers.

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.